Royal London Asset Management Ltd. Sells 75,224 Shares of Thermo Fisher Scientific Inc. $TMO

Royal London Asset Management Ltd. lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 433,314 shares of the medical research company’s stock after selling 75,224 shares during the period. Royal London Asset Management Ltd. owned about 0.12% of Thermo Fisher Scientific worth $217,246,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in TMO. Legacy Wealth Managment LLC ID boosted its holdings in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 22 shares during the period. Kilter Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $25,000. Allied Private Wealth LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth approximately $26,000. High Note Wealth LLC raised its holdings in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares during the last quarter. Finally, JPL Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $28,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This trade represents a 7.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. The trade was a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on TMO. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Royal Bank Of Canada lifted their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. Finally, Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Trading Down 1.4%

NYSE TMO opened at $621.87 on Friday. The stock’s 50 day moving average is $558.64 and its 200 day moving average is $512.08. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $229.94 billion, a PE ratio of 33.45, a P/E/G ratio of 2.57 and a beta of 0.85. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.